Cytotherapy and Longevity (CL), adhering to its core mission of "promoting human health and functional longevity through cell therapy," is committed to advancing collaborative innovation in cell therapy, mechanobiology, and the prevention and treatment of degenerative diseases. The journal focuses on the multidisciplinary field of cell therapy related to human aging, covering the entire industry chain of research, including various cell types from different sources and their mechanobiological regulatory mechanisms, the development and clinical translation of cell therapies targeting multiple frailty-related diseases, cell culture and process optimization using physical regulation techniques in a mechanobiological microenvironment, cell function testing and the application of clinical efficacy data, the development of intelligent mechanobiological intervention technologies and equipment, and the validation of the efficacy of cell therapy in degenerative diseases. It also promotes the translational application of innovative technologies from kinetic medicine, mechanics, biomechanics, and mechanobiology in combined mechano-immuno-regenerative therapies. To comprehensively present the latest achievements and development trends in this field, CL will feature special columns such as reviews and outlooks, technical exchanges, and case studies to gather cutting-edge perspectives and practical experiences from scholars both domestically and internationally; systematically introduce the latest advances in cell therapy in delaying physical decline, enhancing motor function, and improving quality of life; and provide technical support for related clinical practices and industrial development.